In TIME, TGF-β1 produced by cancer cells, stromal fibroblasts, and other cells further promotes cancer progression by shaping tumor structure and inhibiting the activity of anti-tumor immune responses, thereby creating an immunosuppressive microenvironment that prevents or weakens the efficacy of anticancer immunotherapy [78]. This evidence concerns the gene TGFB1 and neoplasm.